_version_ 1785090614783639552
author Luca Morelli, Gian
Fili, Carla
Mauro, Endri
Maria Scattolin, Anna
Mosna, Federico
Gurrieri, Carmela
Nadali, Gianpaolo
Lico, Albana
Sperotto, Alessandra
DE Bellis, Eleonora
Michieli, Mariagrazia
Aloisi, Teresa
Lazzarotto, Davide
Elena Zannier, Maria
Simeone, Erica
Alzetta, Daniel
Battaglia, Giulia
Callegari, Chiara
Pizzano, Umberto
Mullai, Rikard
Tosoni, Luca
Tiribelli, Mario
Fanin, Renato
author_facet Luca Morelli, Gian
Fili, Carla
Mauro, Endri
Maria Scattolin, Anna
Mosna, Federico
Gurrieri, Carmela
Nadali, Gianpaolo
Lico, Albana
Sperotto, Alessandra
DE Bellis, Eleonora
Michieli, Mariagrazia
Aloisi, Teresa
Lazzarotto, Davide
Elena Zannier, Maria
Simeone, Erica
Alzetta, Daniel
Battaglia, Giulia
Callegari, Chiara
Pizzano, Umberto
Mullai, Rikard
Tosoni, Luca
Tiribelli, Mario
Fanin, Renato
author_sort Luca Morelli, Gian
collection PubMed
description
format Online
Article
Text
id pubmed-10429036
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104290362023-08-17 P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”. Luca Morelli, Gian Fili, Carla Mauro, Endri Maria Scattolin, Anna Mosna, Federico Gurrieri, Carmela Nadali, Gianpaolo Lico, Albana Sperotto, Alessandra DE Bellis, Eleonora Michieli, Mariagrazia Aloisi, Teresa Lazzarotto, Davide Elena Zannier, Maria Simeone, Erica Alzetta, Daniel Battaglia, Giulia Callegari, Chiara Pizzano, Umberto Mullai, Rikard Tosoni, Luca Tiribelli, Mario Fanin, Renato Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429036/ http://dx.doi.org/10.1097/01.HS9.0000969104.08302.5e Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Luca Morelli, Gian
Fili, Carla
Mauro, Endri
Maria Scattolin, Anna
Mosna, Federico
Gurrieri, Carmela
Nadali, Gianpaolo
Lico, Albana
Sperotto, Alessandra
DE Bellis, Eleonora
Michieli, Mariagrazia
Aloisi, Teresa
Lazzarotto, Davide
Elena Zannier, Maria
Simeone, Erica
Alzetta, Daniel
Battaglia, Giulia
Callegari, Chiara
Pizzano, Umberto
Mullai, Rikard
Tosoni, Luca
Tiribelli, Mario
Fanin, Renato
P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
title P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
title_full P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
title_fullStr P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
title_full_unstemmed P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
title_short P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
title_sort p549: efficacy and toxicity of cpx-351 in patients with high-risk acute myeloid leukemia (aml): the multicenter real-world experience from the “italian triveneto registry”.
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429036/
http://dx.doi.org/10.1097/01.HS9.0000969104.08302.5e
work_keys_str_mv AT lucamorelligian p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT filicarla p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT mauroendri p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT mariascattolinanna p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT mosnafederico p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT gurriericarmela p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT nadaligianpaolo p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT licoalbana p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT sperottoalessandra p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT debelliseleonora p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT michielimariagrazia p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT aloisiteresa p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT lazzarottodavide p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT elenazanniermaria p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT simeoneerica p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT alzettadaniel p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT battagliagiulia p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT callegarichiara p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT pizzanoumberto p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT mullairikard p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT tosoniluca p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT tiribellimario p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry
AT faninrenato p549efficacyandtoxicityofcpx351inpatientswithhighriskacutemyeloidleukemiaamlthemulticenterrealworldexperiencefromtheitaliantrivenetoregistry